RE:RE:RE:share buybackThey were a few small sales by Wilson and Raghubir around the time of the annual share grant (RSUs). Hardly cause for concern.
The three discontinued products totaled less than $2M in revenue in 2021. Of course this headwind will reduce the growth rate in 2022, but important to keep in mind that only one was meaningfully profitable. Yes, Q4 benefited from an inventory build on those, and an unusually large Protect-It order, but was the impressive bottom line was largely reduced launch spend on Combogesic and Tibella.
I think 2022 can still be a growth year, plus operating margins returning to 30%+. Next Feramax launch coming later this year. Several international orders already. Tibella gaining traction. Early indications for Combogesic don't seem very promising but it's been a tough launch environment. Honestly my optimism for it faded when I learned it was being scheduled behind the counter. Still, the dental niche seems to be working. Overall, management must be optimistic. Several sales reps hired in Q1 plus 7 more job openings on the website (5 in sales and marketing).
prophetoffact wrote: There's been insider selling around $9.
I think the last quarter may not be representative as RX is now no longer selling some products and there was inventory building by clients ahead of the transition. Listen to the Q4 video for detail.
Next month is Q1.